Quarterly report · Q2
4564.TEDINET S100PGWR
Period2022-04-01 → 2022-09-30
Filed2022-11-07
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥515m | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥241m | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | −¥618m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | −¥949m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | −¥644m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥952m | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥613m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥1.2bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥614m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.2bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥614m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | −¥1.2bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥1.7bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥2.7bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥3.7bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥340m | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥705m | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.3bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥2.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.1bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.3bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.3bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.1bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥517m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥7m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥468m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥25m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.3bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-3.19 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.74 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.72 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.74 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.72 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 76.3% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.2% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 29
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥111,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥111,000 |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥188m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥507m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥507m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥48m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥8m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥8m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥111,000 |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥382m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥515m |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥515m |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥111,000 |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | −¥430m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥8m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥8m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥195m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥243m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥234m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥8m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | −¥63m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥6m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥6m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥111,000 |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | −¥691m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥249m |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥241m |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥8m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | −¥754m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 443
| Item | Context | Value | Unit |
|---|---|---|---|
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 6354000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 242697000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 249051000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -8444000 | JPY |
| Net sales | Prior1YTDDuration | 240607000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | -691321000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | -62822000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | -754143000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -194620000 | JPY |
| Operating income | Prior1YTDDuration | -948764000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 7885000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 506680000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 514566000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 514566000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 111000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 111000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -111000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 7996000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 506680000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 514677000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -111000 | JPY |
| Net sales | CurrentYTDDuration | 514566000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | -382023000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | -48050000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | -430073000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -188004000 | JPY |
| Operating income | CurrentYTDDuration | -618078000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-11-07 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第22期第２四半期（自 2022年７月１日 至 2022年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)オンコセラピー・サイエンス株式会社 | |
| Company name in english cover page | FilingDateInstant | OncoTherapy Science, Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 嶋田 順一 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)神奈川県川崎市高津区坂戸三丁目２番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 044－820－8251 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役管理本部長 朴 在賢 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)神奈川県川崎市高津区坂戸三丁目２番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 044－820－8251 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役管理本部長 朴 在賢 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E05363 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45640 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)オンコセラピー・サイエンス株式会社 | |
| Filer name in english | FilingDateInstant | OncoTherapy Science, Inc. |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |